European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS

Early detection of tumor DNA in liquid biopsies as a biomarker of cancer recurrence

Descrizione del progetto

Rilevamento ultrasensibile e rapido per la recidiva tumorale della testa e del collo

Le recidive successive all’iniziale remissione della malattia costituiscono la causa principale di morte correlata al cancro. La start-up danese Cyclomics ha sviluppato una tecnologia di rilevamento del DNA tumorale circolante per la recidiva del tumore della testa e del collo, che rileva le mutazioni nel gene TP53. La sua innovativa metodologia di sequenziamento consente di rilevare in modo affidabile, rapido e ultrasensibile le recidive tumorali nei campioni di sangue e nelle biopsie liquide. La maggior parte dei pazienti affetti da tumore della testa e del collo presentano mutazioni del gene TP53 e quindi l’applicazione di questa tecnologia innovativa costituisce anche un’importante opportunità commerciale per l’azienda. Lo studio di fattibilità condotto nell’ambito del progetto ONCOTECT, finanziato dall’UE, consentirà di acquisire informazioni cruciali sulla strategia di commercializzazione.

Obiettivo

Cyclomics BV is a Dutch start-up company with the ambition to disrupt the cancer diagnostics market with its proprietary circulating tumor (ct) DNA detection technology. Cyclomics has developed a ground-breaking sequencing methodology that enables reliable, fast and ultra-sensitive detection of cancer recurrence from blood samples (liquid biopsies).
The first product, ONCOTECT, detects oncogenic mutations in the TP53 gene, and is developed for accurate and early detection of head and neck cancer (HNC) recurrence. Recurrent disease after initial remission is a main cause of cancer-related death. In HNC, radiological examination is the current standard in detecting cancer lesions but is unable to reliably detect recurrence early on, leading to treatment delays and lower survival rates. Integration of the ONCOTECT assay into routine clinical workflow is inexpensive and will provide faster time-to-results relative to competing sequencing methods.
Since 90% of HNC patients carry specific oncogenic DNA mutations in the TP53 gene, the first application of this novel technology in recurrent HNC presents a considerable market opportunity for ONCOTECT. After achieving clinical proof-of-concept in a cohort of 20 patients, Cyclomics will offer its technology for licensing to a diagnostics company to further develop ONCOTECT as an in vitro diagnostic (IVD) kit and bring it to the market, with the aim of enabling superior quality in diagnostic and clinical decision making. ONCOTECT focuses on TP53 but the underlying technology can be applied to many different genes. Leveraging this potential, Cyclomics’ long-term vision includes monitoring of cancer treatment response and early screening programs, encompassing various genes and cancer types, with the potential to impact the full spectrum of cancer care. In this SME feasibility study, Cyclomics will obtain critical insight for commercialization strategy, including freedom to operate (FTO), user needs and regulatory requirements.

Invito a presentare proposte

H2020-EIC-SMEInst-2018-2020

Vedi altri progetti per questo bando

Bando secondario

H2020-SMEInst-2018-2020-1

Meccanismo di finanziamento

SME-1 - SME instrument phase 1

Coordinatore

CYCLOMICS BV
Contribution nette de l'UE
€ 50 000,00
Indirizzo
MOSKEEPLEIN 82
3531 BX UTRECHT
Paesi Bassi

Mostra sulla mappa

PMI

L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.

Regione
West-Nederland Utrecht Utrecht
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Costo totale
€ 71 429,00